Navigation Links
BD Issues 2010 Sustainability Report
Date:5/19/2011

FRANKLIN LAKES, N.J., May 19, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the publication of its 2010 Sustainability Report.  The report reaffirms the commitment of BD's 29,000 dedicated associates worldwide to pursuing the Company's purpose, "Helping all people live healthy lives," and doing so in a way that is centered on balancing the "triple-bottom-line" – achieving strong economic performance, promoting environmental stewardship and advancing social responsibility.

"In 2010, we continued to observe the strong connections between global health challenges and global environmental issues – and the role that BD can play in making progress in both areas," said Edward J. Ludwig, Chairman and Chief Executive Officer.  "We continue to make progress and believe that our sustainability strategy drives our creativity. It helps us to be more innovative with regard to our actions, products, services and collaborations, which in turn drive growth and operating excellence."

BD's commitment to helping to provide affordable, accessible medical technologies that help address fundamental healthcare needs has been embedded in BD's culture since the Company's founding in 1897.  Today, BD also recognizes the importance of strong environmental performance, and aspires to be recognized as the most environmentally responsible company in its industry.

The 2010 Sustainability Report highlights BD's priorities and performance in areas including:

  • Society: BD is focused on making contributions to society through its worldwide business operations, including the medical devices, instrument systems and reagents that it manufactures and sells, and is dedicated to improving people's health throughout the world.  BD supplements these contributions by giving time, talent and resources to improve global health standards and access to healthcare for all communities. The report highlights BD's strategic collaborations.

  • Fundamental Healthcare Needs:  BD's strategy is to increase sustainable revenue growth by serving as a global leader in developing and applying technologies to solve emerging, sometimes underappreciated, but important and fundamental healthcare problems.  The report highlights BD's work to address important healthcare issues, such as healthcare-associated infections (HAIs), women's health and cancer, and diabetes.

  • Product Responsibility:  BD products play a key role in the discovery, diagnosis and treatment of disease, through an approach that includes integrating safety-engineering features into our products design. The report highlights continued efforts on healthcare worker and patient safety, as well as BD's approach to working with suppliers on sustainability.

  • Associates:  The success of BD's business depends on the creativity, innovation and commitment of the 29,000 people it employs in more than 50 countries around the world. The report highlights BD's commitment to associate health and safety, learning and development, and diversity and inclusion.

  • The Environment:  BD has a clear strategy to reduce its environmental footprint while supporting the efforts of its customers and suppliers to do the same, through an approach that extends throughout the integrated supply chain.  The report highlights progress toward BD's 2015 Sustainability Targets, and the achievement of meeting three of these targets – hazardous waste reduction, renewable energy use and water reduction – ahead of schedule.

2010 Awards and Recognition highlights include:

  • BD has been included on the Dow Jones Sustainability World Index for five consecutive years.
  • BD was ranked #2 in the Healthcare industry and #24 overall in Newsweek's 2010 Green Rankings.
  • BD has been named one of the "World's Most Ethical Companies" by Ethisphere since 2007.
  • BD was awarded a 2010 Green Power Leadership Award in the Green Power Purchaser category by the U.S. Environmental Protection Agency (EPA).

BD's 2010 Sustainability Report is available online at www.bd.com/sustainability.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world.  BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines.  The Company's capabilities are instrumental in combating many of the world's most pressing diseases.  Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world.  The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public.  For more information, please visit www.bd.com.

Contact:
Colleen T. White, Corporate Communications – 201-847-5369
Monique Dolecki, Investor Relations – 201-847-5453


'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
Breaking Medicine News(10 mins):